Nuvalent, Inc.
NUVL
Rang in aandelen
#2104
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to... Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Aandeelprijs
$123.96
Laatst gesynchroniseerd: 2026-07-21
Marktkapitalisatie
$9.75B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
26.53%
Land
US
Handel Nuvalent, Inc. (NUVL)
Categorie
Healthcare
EPS voor Nuvalent, Inc. (NUVL)
EPS per March 2026 TTM: $-6.06
Volgens de laatste financiële rapporten en de aandelenkoers van Nuvalent, Inc. is de huidige EPS van het bedrijf (TTM) $-6.06. Eind 2023 had het bedrijf een EPS van $-2.17, een stijging ten opzichte van de EPS van 2022 die $-1.65 bedroeg.
EPS-geschiedenis van Nuvalent, Inc. van 2019 tot 2026
EPS aan het einde van elk jaar
| Jaar | EPS | Wijzigen |
|---|---|---|
| 2026 (TTM) | $-6.06 | 54.20% |
| 2024 | $-3.93 | 81.11% |
| 2023 | $-2.17 | 31.52% |
| 2022 | $-1.65 | -22.54% |
| 2021 | $-2.13 | 232.81% |
| 2020 | $-0.64 | 166.67% |
| 2019 | $-0.24 | 0.00% |
EPS van vergelijkbare bedrijven of concurrenten
| Bedrijf | EPS | EPS-verschil | Land |
|---|---|---|---|
| $17.32 | -385.81% |
US
|
|
| $-7.98 | 31.68% |
US
|
|
| $-5.29 | -12.71% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -557.76% |
NL
|
